Princess Margaret Cancer Centre-ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2022

  1. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

    New England Journal of Medicine, Vol. 387, Núm. 3, pp. 217-226

2021

  1. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

    The Lancet, Vol. 396, Núm. 10265, pp. 1817-1828

2019

  1. Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

    Annals of Oncology, Vol. 30, Núm. 3, pp. 365-373